James Hindman
Director/Board Member at ACCURAY INCORPORATED
Net worth: 519 278 $ as of 30/04/2024
Profile
James M.
Hindman currently holds several director positions at NeuroSigma, Inc., Accuray, Inc., Amolyt Pharma SAS, Aatru Medical LLC, and Urovant Sciences Ltd.
He also serves as Treasurer at Vicept Therapeutics, Inc. and as a Member-Regents Board at Loyola Marymount University.
In the past, he held director positions at Millendo Therapeutics US, Inc., Sienna Biopharmaceuticals, Inc., Urovant Sciences, Inc., and Millendo Therapeutics, Inc. He was also President & Director at Allergan Foundation and served as CFO, EVP-Finance & Business Development at Allergan, Inc. Hindman received his undergraduate degree from Loyola Marymount University and his MBA from Pepperdine University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ACCURAY INCORPORATED
0.24% | 30/11/2023 | 238,201 ( 0.24% ) | 519 278 $ | 30/04/2024 |
James Hindman active positions
| Companies | Position | Start |
|---|---|---|
| ACCURAY INCORPORATED | Director/Board Member | 06/09/2019 |
| UROVANT SCIENCES LTD. | Director/Board Member | 20/05/2020 |
Vicept Therapeutics, Inc.
 Vicept Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Vicept Therapeutics Inc. develops dermatologic therapeutic products. The firm develops topical agents for the treatment and prevention of a number of medical and cosmetic indications including bruising of the skin. The company was founded on July 1, 2009 by Neal Walker, Stewart D. Shanler, and Christopher V. Powala and is headquartered in Malvern, PA. | Treasurer | - |
NeuroSigma, Inc.
 NeuroSigma, Inc. Medical SpecialtiesHealth Technology NeuroSigma, Inc. operates as a life sciences company which develops bioelectronic technologies to treat major neurological and neuropsychiatric disorders such as epilepsy and depression. Its non-invasive external trigeminal nerve stimulation system (eTNS) employs trigeminal nerve stimulation, or TNS, as adjunctive therapy for drug-resistant epilepsy and major depressive disorder. The company was founded by Leon Ekchian in March 2008 and is headquartered in Los Angeles, CA. | Director/Board Member | 01/02/2014 |
| Loyola Marymount University | Director/Board Member | 01/06/2015 |
Aatru Medical LLC
 Aatru Medical LLC Medical SpecialtiesHealth Technology Aatru Medical LLC provides wound and damaged skin treatment. The company was incorporated in 2017 and is headquartered in Cleveland, OH. | Director/Board Member | 01/11/2018 |
Amolyt Pharma SAS
 Amolyt Pharma SAS Pharmaceuticals: MajorHealth Technology Amolyt Pharma SAS engages in development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases. The company was founded by Thierry Abribat in 2014 and is headquartered in Ecully, France. | Director/Board Member | 30/06/2021 |
Former positions of James Hindman
| Companies | Position | End |
|---|---|---|
Urovant Sciences, Inc.
 Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The private company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | Director/Board Member | 01/03/2023 |
| MILLENDO THERAPEUTICS | Director/Board Member | 25/06/2021 |
| ░░░░░░░░ ░░░░░░░░░░░░ ░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
Training of James Hindman
| Pepperdine University | Masters Business Admin |
| Loyola Marymount University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| SIENNA BIOPHARMACEUTICALS, INC. | Health Technology |
| ACCURAY INCORPORATED | Health Technology |
| Private companies | 10 |
|---|---|
Allergan, Inc.
 Allergan, Inc. Pharmaceuticals: MajorHealth Technology Allergan, Inc. operated as a global healthcare company. It engaged in the development and commercialization of specialty pharmaceutical, medical device ,and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological, and other specialty markets. The company was founded by Gavin S. Herbert Sr. in 1950 and headquartered in Irvine, CA. | Health Technology |
Vicept Therapeutics, Inc.
Vicept Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Vicept Therapeutics Inc. develops dermatologic therapeutic products. The firm develops topical agents for the treatment and prevention of a number of medical and cosmetic indications including bruising of the skin. The company was founded on July 1, 2009 by Neal Walker, Stewart D. Shanler, and Christopher V. Powala and is headquartered in Malvern, PA. | Health Technology |
| Allergan Foundation | |
NeuroSigma, Inc.
NeuroSigma, Inc. Medical SpecialtiesHealth Technology NeuroSigma, Inc. operates as a life sciences company which develops bioelectronic technologies to treat major neurological and neuropsychiatric disorders such as epilepsy and depression. Its non-invasive external trigeminal nerve stimulation system (eTNS) employs trigeminal nerve stimulation, or TNS, as adjunctive therapy for drug-resistant epilepsy and major depressive disorder. The company was founded by Leon Ekchian in March 2008 and is headquartered in Los Angeles, CA. | Health Technology |
Millendo Therapeutics US, Inc.
 Millendo Therapeutics US, Inc. Pharmaceuticals: MajorHealth Technology Millendo Therapeutics US, Inc. engages in the development of novel treatment for adrenal cancer. It focuses on developing a portfolio of disease-modifying treatments for endocrine disorders caused by hormone dysregulation. The company was founded by Raili E. Kerppola, Julia C. Owens, and Gary D. Hammer in January 2012 and is headquartered in Ann Arbor, MI. | Health Technology |
Millendo Therapeutics, Inc.
 Millendo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Millendo Therapeutics, Inc. is a biopharmaceutical company, which engages in seeking distinct and transformative treatments where there is a significant unmet medical need. The company was founded by Julia C. Owens in January 2012 and is headquartered in Ann Arbor, MI. | Health Technology |
Aatru Medical LLC
Aatru Medical LLC Medical SpecialtiesHealth Technology Aatru Medical LLC provides wound and damaged skin treatment. The company was incorporated in 2017 and is headquartered in Cleveland, OH. | Health Technology |
Urovant Sciences Ltd.
 Urovant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which through its subsidiaries, engages in the development and commercialization of therapies for urologic conditions. Its pipeline includes Vibegron (RVT-901) and URO-902. The company was founded on January 27, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
Amolyt Pharma SAS
Amolyt Pharma SAS Pharmaceuticals: MajorHealth Technology Amolyt Pharma SAS engages in development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases. The company was founded by Thierry Abribat in 2014 and is headquartered in Ecully, France. | Health Technology |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The private company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | Health Technology |
- Stock Market
- Insiders
- James Hindman